| Literature DB >> 28273059 |
Chuanyuan Tao1, Xin Hu1, Jiajing Wang2, Chao You1.
Abstract
BACKGROUND Cerebellar hemorrhage (CH) has a quite different treatment strategy and prognostic factors compared with supratentorial intracerebral hemorrhage (ICH). The prognostic role of hyperglycemia has been discussed mainly in cases of supratentorial hemorrhage; it remains to be elucidated following CH. We aimed to determine the association of hyperglycemia on admission with 6-month functional outcome in CH patients. MATERIAL AND METHODS We retrospectively analyzed 77 patients with acute CH between September 2010 and April 2015 in West China Hospital. Blood glucose level was measured when the patients were admitted. Primary outcome was 6-month functional outcome, which could comprehensively reflect the patient's recovery of physical and social ability after stroke and was assessed by the modified Rankin scale (mRS). Association of hyperglycemia with functional outcome was identified in logistic regression models. RESULTS There were 50 (64.9%) patients with poor functional outcomes. Patients with poor outcome were much older (P<0.001) and had a significantly higher glucose level on admission (P<0.001), a lower Glasgow Coma Scale score (P<0.001), a larger hematoma (P=0.003), and a higher incidence of intraventricular extension (P=0.002), brainstem compression (P=0.013), and hydrocephalus (P=0.023). Multivariate analysis showed that hyperglycemia (OR 1.50, 95% CI 1.07-2.08, P=0.017 when glucose level was analyzed as a continuous variable; OR 7.46, 95% CI 1.41-39.51, P=0.018 when glucose level was dichotomized by the critical threshold of 6.78 mmol/L) emerged as an independent predictor for adverse functional outcome at 6 months. CONCLUSIONS To the best of our knowledge, this is the first study focusing on the relationship between hyperglycemia and long-term functional outcome after CH. The study combined with previous pertinent reports definitely indicates the poor effect of hyperglycemia on both supra- and infratentorial ICH independent of hemorrhage site. Therefore, further controlled trials are urgently needed to evaluate the benefits of glucose-lowing treatment.Entities:
Mesh:
Year: 2017 PMID: 28273059 PMCID: PMC5353882 DOI: 10.12659/msm.900202
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Baseline characteristics and variables related to 6-month outcome in patients with CH.
| Variable | Total (n=77) | 6-month outcome | ||
|---|---|---|---|---|
| Good (n=27) | Poor (n=50) | |||
| Demographic data | ||||
| Age | 64.7±13.6 | 56.7±13.2 | 69.0±11.9 | <0.001 |
| Men | 50 (64.9) | 19 (70.4) | 31 (62.0) | 0.463 |
| Clinical data | ||||
| Hypertension | 40 (51.9) | 13 (48.1) | 27 (54.0) | 0.624 |
| Diabetes mellitus | 9 (11.7) | 2 (7.4) | 7 (14.0) | 0.481 |
| Drinking | 14 (18.2) | 4 (14.8) | 10 (20) | 0.759 |
| Smoking | 19 (24.7) | 7 (25.9) | 12 (24.0) | 0.852 |
| SBP | 177±33 | 177±33 | 177±34 | 0.991 |
| DBP | 102±20 | 105±20 | 100±21 | 0.280 |
| GCS score | 12 (9, 14) | 14 (13, 15) | 11 (8, 12) | <0.001 |
| Radiological data | ||||
| Hemorrhage location | 0.482 | |||
| LH | 34 (44.2) | 11 (40.7) | 23 (46.0) | |
| RH | 19 (24.7) | 9 (33.3) | 10 (20.0) | |
| Vermis | 6 (7.8) | 1 (3.7) | 5 (10.0) | |
| LH+vermis | 8 (10.4) | 2 (7.4) | 6 (12.0) | |
| RH+vermis | 8 (10.4) | 4 (14.8) | 4 (8.0) | |
| LH+RH+vermis | 2 (2.6) | 0 (0) | 2 (4.0) | |
| Presence of SAH | 26 (33.8) | 8 (29.6) | 18 (36.0) | 0.573 |
| Presence of IVH | 36 (46.8) | 6 (22.2) | 30 (60.0) | 0.002 |
| FVC | 32 (41.6) | 9 (33.3) | 23 (46.0) | 0.282 |
| BSC | 22 (28.6) | 3 (11.1) | 19 (38.0) | 0.013 |
| Hydrocephalus | 24 (31.2) | 4 (14.8) | 20 (40.0) | 0.023 |
| Hematoma size(cm) | 3.3±1.2 | 2.8±1.1 | 3.6±1.2 | 0.003 |
| Glucose | 9.0 (7.2, 11.5) | 7.3 (6.0, 9.1) | 10.0 (7.9, 12.9) | <0.001 |
| Surgery | 21 (27.3) | 7 (25.9) | 14 (28.0) | 0.845 |
CH – cerebellar hemorrhage; SBP – systolic blood pressure; DBP – diastolic blood pressure; GCS – Glasgow Coma Scale; LH – left hemisphere; RH – right hemisphere; SAH – subarachnoid hemorrhage; IVH – intraventricular hemorrhage; FVC – fourth ventricle compression; BSC – brainstem compression.
Mean ±SD;
n (%);
median (25th–75th percentiles).
Baseline characteristics and variables related to 6-month outcome in non-diabetic patients with CH.
| Variable | Total (n=68) | 6-month outcome | ||
|---|---|---|---|---|
| Good (n=25) | Poor (n=43) | |||
| Demographic data | ||||
| Age | 64.8±13.8 | 57.1±13.3 | 69.3±12.2 | <0.001 |
| Men | 47 (69.1) | 18 (72.0) | 29 (67.4) | 0.695 |
| Clinical data | ||||
| Hypertension | 34 (50.0) | 12 (48.0) | 22 (51.2) | 0.801 |
| Drinking | 12 (17.6) | 3 (12.0) | 9 (20.9) | 0.513 |
| Smoking | 18 (26.5) | 6 (24.0) | 12 (27.9) | 0.725 |
| SBP | 178±34 | 177±34 | 178±34 | 0.891 |
| DBP | 102±21 | 105±21 | 100±22 | 0.378 |
| GCS score | 12 (10, 14) | 14 (13, 15) | 11 (8, 13) | <0.001 |
| Radiological data | ||||
| Hemorrhage location | 0.178 | |||
| LH | 30 (44.1) | 11 (44.0) | 19 (44.2) | |
| RH | 17 (25.0) | 9 (36.0) | 8 (18.6) | |
| Vermis | 5 (7.4) | 0 (0) | 5 (11.6) | |
| LH+vermis | 6 (8.8) | 1 (4.0) | 5 (11.6) | |
| RH+vermis | 8 (11.8) | 4 (16.0) | 4 (9.3) | |
| LH+RH+vermis | 2 (2.9) | 0 (0) | 2 (4.7) | |
| Presence of SAH | 20 (29.4) | 6 (24.0) | 14 (32.6) | 0.455 |
| Presence of IVH | 31 (45.6) | 6 (24.0) | 25 (58.1) | 0.006 |
| FVC | 27 (39.7) | 7 (28.0) | 20 (46.5) | 0.133 |
| BSC | 20 (29.4) | 3 (12.0) | 17 (39.5) | 0.016 |
| Hydrocephalus | 21 (30.9) | 4 (16.0) | 17 (39.5) | 0.043 |
| Hematoma size (cm) | 3.3±1.3 | 2.7±1.1 | 3.7±1.3 | 0.002 |
| Glucose | 8.6 (6.8, 10.2) | 6.8 (5.9, 8.8) | 9.4 (7.7, 11.8) | <0.001 |
| Surgery | 17 (25.0) | 6 (24.0) | 11 (25.6) | 0.885 |
CH – cerebellar hemorrhage; SBP – systolic blood pressure; DBP – diastolic blood pressure; GCS – Glasgow Coma Scale; LH – left hemisphere; RH – right hemisphere; SAH – subarachnoid hemorrhage; IVH – intraventricular hemorrhage; FVC – fourth ventricle compression; BSC – brainstem compression.
Mean ±SD;
n (%);
median (25th–75th percentiles).
Predictors of 6-month functional outcome in patients with CH in multiple logistic regression model.
| Variable | Glu as continuous variable | Glu as categorical variable (> 6.78 mmol/L) | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P | OR | 95%CI | P | |
| Age | 1.13 | 1.05–1.22 | 0.001 | 1.12 | 1.04–1.19 | 0.001 |
| GCS | 0.58 | 0.39–0.86 | 0.007 | 0.57 | 0.39–0.82 | 0.003 |
| Presence of IVH | 2.53 | 0.50–12.7 | 0.261 | 2.79 | 0.58–13.37 | 0.200 |
| BSC | 2.88 | 0.42–19.86 | 0.283 | 2.10 | 0.30–14.55 | 0.452 |
| hydrocephalus | 1.26 | 0.19–8.24 | 0.810 | 1.45 | 0.25–8.46 | 0.677 |
| Diameter ≥3 cm | 0.76 | 0.12–4.93 | 0.772 | 1.01 | 0.17–5.91 | 0.992 |
| Glu | 1.50 | 1.07–2.08 | 0.017 | 7.46 | 1.41–39.51 | 0.018 |
CH – cerebellar hemorrhage; Glu – glucose; OR – odd ratio; CI – confidence interval; GCS – Glasgow Coma Scale; IVH – intraventricular hemorrhage; BSC – brainstem compression.
Predictors of 6-month functional outcome in non-diabetic patients with CH in multiple logistic regression model.
| Variable | Glu as continuous variable | Glu as categorical variable (>6.78 mmol/L) | ||||
|---|---|---|---|---|---|---|
| OR | 95%CI | P | OR | 95%CI | P | |
| Age | 1.14 | 1.05–1.24 | 0.002 | 1.12 | 1.04–1.21 | 0.003 |
| GCS | 0.56 | 0.36–0.89 | 0.015 | 0.55 | 0.36–0.84 | 0.006 |
| Presence of IVH | 2.18 | 0.36–13.15 | 0.395 | 2.42 | 0.48–12.24 | 0.284 |
| BSC | 2.30 | 0.35–15.32 | 0.388 | 1.06 | 0.12–9.73 | 0.960 |
| hydrocephalus | 0.76 | 0.09–6.72 | 0.808 | 1.08 | 0.15–7.84 | 0.573 |
| Diameter ≥3 cm | 1.27 | 0.18–8.82 | 0.809 | 1.58 | 0.32–7.75 | 0.617 |
| Glu | 1.85 | 1.13–3.03 | 0.015 | 8.49 | 1.51–47.64 | 0.015 |
CH – cerebellar hemorrhage; Glu – glucose; OR – odd ratio; CI – confidence interval; GCS – Glasgow Coma Scale; IVH – intraventricular hemorrhage; BSC – brainstem compression.
Spearman correlation analyses of the correlation of admission Glu level with clinical parameters in patients with CH.
| Clinical parameter | Glu | |
|---|---|---|
| r | p | |
| Age, years | −0.020 | 0.865 |
| Diabetes mellitus | 0.641 | <0.001 |
| Location of CH | −0.037 | 0.750 |
| IVH | 0.125 | 0.278 |
| Hematoma size | 0.371 | 0.001 |
| GCS score | −0.437 | <0.001 |
| FVC | 0.137 | 0.234 |
| BSC | 0.144 | 0.211 |
| Hydrocephalus | 0.200 | 0.081 |
Glu – glucose; CH – cerebellar hemorrhage; IVH – intraventricular hemorrhage; GCS – Glasgow Coma Scale; FVC – fourth ventricle compression; BSC – brainstem compression.
Multiple linear regression of admission glucose and admission variables in patients with CH.
| Variable | Standardized Coefficient | P value |
|---|---|---|
| Diabetes mellitus | 6.433 | <0.001 |
| Hematoma size | 0.634 | 0.020 |
| GCS score | −0.228 | 0.030 |
| Hydrocephalus | 0.377 | 0.552 |
CH – cerebellar hemorrhage; GCS – Glasgow Coma Scale.